Psoriasis Drugs Market Size to Enlarge with Growing Revenue at 9.6% of CAGR till 2027

Market Size – USD 16.21 Billion in 2018, Market Growth - CAGR of 9.6%, Market Trends – The rising demand for Interleukin Inhibitors
By: Reports And Data
Spread the Word
Listed Under

* Psoriasis Drugs Market

* Health

* New York City - New York - US

NEW YORK - Jan. 23, 2020 - PRLog -- The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027, according to a new report by Reports and Data. Psoriasis can be defined as a skin condition, which accelerates the life cycle of skin cells. It results in cells to develop on the surface. It is usually considered to be a chronic condition. The condition has an unpredictable course of symptoms, significant comorbidities, and various external triggers impacting the condition that includes metabolic syndrome, arthritis, and cardiovascular diseases, among others. The immune system is considered to play an integral role in the condition. The condition also affects nails apart from skin. When a particular area on the skin is affected by the disease, the skin lesion is usually localized, which are sharply demarcated by plaques and red papules that are covered by silver or white scales. These lesions are generally symmetrical and cause stinging, itching, and pain. Herein the main aim of the treatment is to prevent the skin cells from growing quickly. There is no cure to the disease; however, these drugs help in managing the symptoms.

Further key findings from the report suggest

• The Psoriasis Drugs market held a market share of USD 16.21 Billion in the year 2018 that is forecasted to grow at a rate of 9.6% during the forecast period.

• In context to Treatment Type, the Biologics segment generated the highest revenue of USD 6.32 Billion in the year 2018, with a growth rate of 9.9% during the forecast period. The ability of these drugs to treat the condition by targeting particular areas of the immune system thereby treating the condition form the base, results in its high acceptance among care providers that contributes to the revenue generated by this segment.

• In context to Therapeutic Class, the Interleukin Inhibitors segment is projected to witness the fastest growth rate of 10.3% during the forecast period, which is expected to occupy 27.5% of the market by 2027. The growth rate witnessed by the segment is attributed to the significant role it plays in the pathogenesis of plaque psoriasis, one of the most common form of psoriasis, which results in its elevated demand among care providers.

·         Key participants include Amgen, Inc., AbbVie Inc., Novartis AG, Johnson & Johnson, AstraZeneca, Eli Lilly and Company, UCB, Celgene Corporation, Merck, and Sun Pharmaceutical Industries Ltd.

Browse full report description @

John Watson
Head of Business Development
Posted By:*** Email Verified
Tags:Psoriasis Drugs Market
Location:New York City - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
40 Wall St. 28th floor New York City News
Most Viewed
Daily News

Like PRLog?
Click to Share